Sab biotherapeutics announces completion of $67.1 million financing to advance potential disease-modifying treatment for type 1 diabetes

Sioux falls, s.d., nov. 14, 2023 (globe newswire) -- sab biotherapeutics, inc. (nasdaq: sabs), a clinical stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (higg) for delaying the onset of progression of type 1 diabetes (t1d), today announced the funding of the second tranche of a previously-announced financing, raising total aggregate proceeds to date of $67.1 million. the proceeds from the financing will be used to fund the development of the company's lead research program, sab-142, a potential disease modifying treatment for t1d.
SABS Ratings Summary
SABS Quant Ranking